Navigation Links
YM BioSciences provides update on AeroLEF(TM) clinical development program
Date:1/17/2008

recently reported that its lead drug, nimotuzumab, is in numerous trials internationally including a Phase III randomized trial in adult glioma and a Phase II/III randomized trial in patients with advanced pancreatic cancer. Data from the fully recruited Phase III trial in Europe in children with inoperable brain cancer, if positive, are expected to be submitted to the EMEA for marketing approval.

About AeroLEF(TM)

AeroLEF(TM) is a unique, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain. In contrast to fixed-dose approaches to opioid delivery, where a significant titration period is often required to determine the suitable dose for the patient, AeroLEF(TM) is being developed as a non-invasive delivery system designed to enable patients to self-titrate. Using AeroLEF(TM), patients can identify and select a personalized dose for each pain episode, achieving both rapid onset and extended duration of analgesia.

About YM BioSciences

YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company has two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF(TM), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such f
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014 Research and Markets has ... Gel Permeation Chromatography (GPC) Industry Report 2014" report ... China Gel Permeation Chromatography (GPC) Industry Report is a ... the global gel permeation chromatography industry with a focus ... basic overview of the industry including definitions, classifications, applications ...
(Date:8/22/2014)... Nerium International, the go-to, buzzworthy skincare ... again. Nerium will showcase its signature NeriumAD® Age-Defying ... Cream to Hollywood’s elite at the official Giving ... Primetime Emmy® Awards. , Developed from cutting-edge research ... show that NeriumAD night cream dramatically reduces the ...
(Date:8/21/2014)...  BioSpecifics Technologies Corp. (NASDAQ: BSTC ... collagenase-based products marketed as XIAFLEX ® (collagenase ... XIAPEX ® in the EU, today announced ... Phase 2a study of CCH for the potential ... results showed that all three doses of CCH ...
(Date:8/21/2014)... research team including DESY scientists has observed tiny quantum ... reports in the journal Science that the ... the nanodroplets. It is the first time that the ... samples of what is known as superfluid helium, have ... best expectations," says Andrey Vilesov of the University of ...
Breaking Biology Technology:Global and China Gel Permeation Chromatography (GPC) Industry Report 2014 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Scientists observe quantum vortices in cold helium droplets 2
... pure proteinTHOUSAND OAKS, Calif., Feb. 24 Bone Biologics, ... organization, Aragen Bioscience, has completed development of a recombinant ... recombinant protein. Bone Biologics has been developing the protein ... ten years of research in the lab performed by ...
... Genencor, a division of Danisco A/S, launched Accellerase(R) ... enzyme product. Genencor introduced the product at the ... in San Antonio, TX.Accellerase(R) 1500 is another significant ... made from cellulosic feedstocks, such as agricultural residues ...
... Ohio, Feb. 24 EyeScience Labs has launched ... comprehensive information and education on age-related macular degeneration (AMD) ... progressive, hereditary eye disease that is the leading cause ... the site, visitors can learn about basic eye anatomy, ...
Cached Biology Technology:Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Biosciences 2Genencor Launches Accellerase(R) 1500, Next Step Toward Scale-Up of Cellulosic Ethanol 2EyeScience Launches Comprehensive Online Resource Devoted to Age-Related Macular Degeneration Education and Prevention 2
(Date:8/22/2014)... of captive black rhino reproduction in Europe highlights ... breeding programmes. , Researchers from Chester Zoo, The ... carried out a six-year study which encompassed 90% ... Katie Edwards led the research as part of ... says: "Although some black rhinoceros breed well in ...
(Date:8/22/2014)... 3β-Hydroxysteroid-Δ24 reductase (DHCR24) is a multifunctional ... reticulum and has neuroprotective and cholesterol-synthesizing ... apoptosis caused by amyloid β deposition. ... Liaoning University in China constructed two ... drive DHCR24 expression specifically in neuronal ...
(Date:8/22/2014)... Stanford, CAEveryone,s heard of the birds and the ... flowers that are being fertilized. The fertilization process ... extensive communication between the male and female reproductive ... Stanford, Regensburg, Heidelberg, and Munich, and including Carnegie,s ... discoveries in the chemical signaling process that guides ...
Breaking Biology News(10 mins):Hormone analysis helps identify horny rhinos 2Calcium and reproduction go together 2
... team of scientists led by University of Hawai,i at ... Florida International University, and Alexander Tielens of Leiden Observatory ... form polycyclic aromatic hydrocarbons (PAHs) complex organic molecules ... ultra-cold regions of interstellar space. The team announced their ...
... Rockville, MD The Association for Research in Vision ... Vision Science & Technology (TVST), with an open ... online only, peer-reviewed journal emphasizing multidisciplinary research that bridges ... The new journal will publish manuscripts in ...
... published online in the FASEB Journal ( http://www.fasebj.org ... the intestines may be used to predict a person,s likelihood ... may help reduce heart attack risk. This discovery may lead ... prevent and treat heart attacks. In addition, this research suggests ...
Cached Biology News:UH Manoa researchers discover novel chemical route to form organic molecules 2UH Manoa researchers discover novel chemical route to form organic molecules 3UH Manoa researchers discover novel chemical route to form organic molecules 4ARVO launches new journal on translational research 2The microbiome and disease: Gut bacteria influence the severity of heart attacks in rats 2
...
Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
Biology Products: